Tarsus Pharmaceuticals (TARS) Non-Current Debt (2022 - 2026)

Tarsus Pharmaceuticals' Non-Current Debt history runs 5 years deep, the most recent figure standing at $72.6 million for Q1 2026.

• In Q1 2026, Non-Current Debt rose 0.85% year-over-year to $72.6 million; the TTM figure through Mar 2026 stood at $72.6 million (up 0.85% YoY), while the FY2025 annual figure was $72.4 million, up 0.83% from the prior year.
• Non-Current Debt was $72.6 million for Q1 2026 at Tarsus Pharmaceuticals, roughly flat from $72.4 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $72.6 million in Q1 2026 to a low of $19.2 million in Q1 2022.
• Historically, Non-Current Debt has averaged $46.6 million across 5 years, with a median of $29.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt soared 190.88% in 2024, then climbed 0.77% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $19.4 million in 2022, then soared by 53.44% to $29.8 million in 2023, then soared by 140.94% to $71.8 million in 2024, then rose by 0.83% to $72.4 million in 2025, then grew by 0.22% to $72.6 million in 2026.
• The last three Non-Current Debt figures came in at $72.6 million (Q1 2026), $72.4 million (Q4 2025), and $72.3 million (Q3 2025), per Business Quant data.